Biotech Stocks


Biotech Stocks

Biotechnology has been one of the fastest advancing industries in the past decade. With new medicine always being synthesized and new ways to fertilize crops, the sector is diverse and prosperous, especially as corporations look for new findings or better efficiency. Subsequently, the biotech stocks are booming and should continue to rise in the future.
Some of the best biotech stocks to buy in 2014 include Amgen (NYSE:AMGN) and Gilead Sciences (NYSE:GILD) although many smaller biotech corporations are on the rise and worth a consideration. Biotech stocks can cure your ailing portfolio and lead you down the road to recovery.

Biotechnology Sector Quote (CIX: MSECTOR5151)

Enough Already! Ditch Moderna Stock

By Thomas Niel, InvestorPlace Contributor
Whether you bought MRNA stock for the CMV or the coronavirus catalyst, it’s clearly time to sell. With shares appearing to be topping out, cashing out today could be the best call.

7 Red-Hot Vaccine Stocks Racing to Develop a Coronavirus Cure

By Luke Lango, InvestorPlace Senior Investment Analyst
A race to develop a coronavirus vaccine is on, and these red-hot Covid-19 vaccine stocks are leading the way.

This Stock Points to the Massive China Biotech Trend

By InvestorPlace Research Staff
There is ridiculously big upside potential for Chinese biotech stocks in the next decade. The spread of the pandemic has only strengthened the case.

Technology Stock Profits Will Only Accelerate in the Post-Pandemic World

By InvestorPlace Research Staff
These must-own investing themes and stocks will continue to pick up steam as the world moves to a new normal after the coronavirus crisis.

Biotech Stocks: Big Buying Opportunities in 2020’s Sector of the Year

By InvestorPlace Research Staff
Yes, many biotech stocks are down at the moment. But that sets up an incredible chance to get some of the best at a discount.

7 Biotech Stocks to Buy That Could Beat the Coronavirus

By Chris Lau, InvestorPlace Contributor
These biotech stocks are all working on treatments that have the potential to beat the coronavirus. Don't just wait for a cure. Buy them now.

Biotech Stocks: Coronavirus Response Shows How Far We’ve Come …

By InvestorPlace Research Staff
Look for biotech stocks as a group to gain more than 20% this year … with the best, most innovative firms more than doubling.

The Top Performing Sector in 2020 Will Be …

By InvestorPlace Research Staff
The future of healthcare will really start to take shape this year, and the next decade will bring advancements that we can only imagine in our wildest dreams.

3 Biotech Stocks to Bank on for Buyouts in 2020

By Aaron Levitt, InvestorPlace Contributor
Flushed with cash, bigger biotech stocks are on the hunt. These 3 smaller drug makers could be the next buyout targets in the new year.

Why We Had to Add This Stock to Our 2020 “Screaming Buy” List

By InvestorPlace Research Staff
Our research and analysis have identified another name in biotech stocks with big potential in 2020.

You Can’t Afford to Miss This Buying Opportunity

By InvestorPlace Research Staff
There's a catalyst on the horizon that could send biotech stocks soaring into the stratosphere.

The Most Overlooked Investment Theme Heading Into 2020

By InvestorPlace Research Staff
Chinese biotech stocks are set for not just 10X growth … not 20X growth … not even 50X growth … but at least 100X growth.

7 Catalysts Pointing to Massive Potential in Chinese Biotech Stocks

By InvestorPlace Research Staff
Even beyond China’s strong support of biotech, there are seven more reasons why investing in the sector will be one of the best wealth-building opportunities of the next 20 years.

Chinese Biotech Stocks: The 100X Play as Big Pharma Money Moves In

By InvestorPlace Research Staff
Investing in Chinese biotech stocks today is similar to getting into U.S. biotech back in the 1990s.

Ocugen Stock Is Nothing More than a Risky Trade on Even-riskier Biotech

By Josh Enomoto, InvestorPlace Contributor
Ocugen gave rise to OCGN stock through a reverse merger with Histogenics. But despite this confusing deal, it really didn't do much for either company in the end.

This $2.7 Billion Deal Is a Shot Across the Bow for Big Pharma

By InvestorPlace Research Staff
Folks who haven’t been paying attention to the absolutely huge potential happening in biotech stocks right now -- both in the U.S. and other parts of the world -- have been put on notice.

One Step Closer to a Medical Game Changer

By InvestorPlace Research Staff
We don’t get many chances to invest in a once-in-a-lifetime, game-changing medical breakthrough. We need to take full advantage.

3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector

By Louis Navellier, Editor, Growth Investor
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).

9 Catalysts That Will Drive Chinese Biotech Stocks Much Higher

By InvestorPlace Research Staff
Matt McCall is extremely bullish on China and the big opportunities in several sectors, but Chinese biotech stocks top his list.
Load More